Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare Capital (SHC), has reportedly secured nearly RMB 200 million (approximately USD 28 million) in a Series A financing round led by Lapam Capital, with participation from SHC. The funds will be allocated to clinical and pre-clinical studies for its existing product pipeline.
Founded in 2021, Synvida has developed a diverse pipeline that addresses conditions such as pulmonary fibrosis, thrombocytopenia, hemophilia, and thrombotic diseases. The company also features the EMPRESS yeast library construction system, a cutting-edge platform for antibody and protein drug discovery and modification based on synthetic biology. Notable drug candidates include the hemophilia A therapeutic antibody SV003 and the long-acting anticoagulant antibody SV004.- Flcube.com
